Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss
Language English Country Switzerland Media print-electronic
Document type Journal Article
PubMed
28027898
DOI
10.1016/j.pan.2016.12.004
PII: S1424-3903(16)31251-0
Knihovny.cz E-resources
- Keywords
- Diabetes mellitus, Glucose-dependent insulinotropic peptide, Pancreatic ductal adenocarcinoma, Pancreatic polypeptide,
- MeSH
- Biomarkers blood MeSH
- Diabetes Mellitus, Type 2 blood complications physiopathology MeSH
- Adult MeSH
- Carcinoma, Pancreatic Ductal blood complications diagnosis physiopathology MeSH
- Glucagon-Like Peptide 1 blood MeSH
- Weight Loss * MeSH
- Blood Glucose metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Pancreatic Neoplasms blood complications diagnosis physiopathology MeSH
- Neuropeptide Y blood MeSH
- Pancreatic Polypeptide blood MeSH
- Peptide YY blood MeSH
- Glucose Intolerance blood complications physiopathology MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Gastric Inhibitory Polypeptide blood MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biomarkers MeSH
- Glucagon-Like Peptide 1 MeSH
- Blood Glucose MeSH
- Neuropeptide Y MeSH
- Pancreatic Polypeptide MeSH
- Peptide YY MeSH
- Gastric Inhibitory Polypeptide MeSH
BACKGROUND: The changes in gastrointestinal hormones associated with pancreatic ductal adenocarcinoma (PDAC) in patients with impaired glucoregulation have yet to be evaluated. The aim of this study was to determine plasma concentrations of selected gastrointestinal hormones in PDAC patients with and without diabetes and to compare them with levels found in Type 2 diabetic patients without cancer. METHODS: In this study we examined plasma concentrations of glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), pancreatic polypeptide (PP), peptide YY (PYY) and neuropeptide Y (NPY), and cytokines leptin and adiponectin in 94 patients with histologically confirmed PDAC. Thirty-nine patients with Type 2 diabetes without PDAC and 29 healthy individuals with no evidence of acute or chronic diseases were examined as controls. RESULTS: Significantly lower plasma concentrations of GIP were found in PDAC patients with new-onset diabetes/prediabetes (n = 76), or in those with normal glucose regulation (n = 18), compared to patients with Type 2 diabetes without PDAC and controls (15.5 (3.7-64.5) or 6.5 (1.7-24.5) vs. 39.8 (15.1-104.7) and 28.8 (7.4-112.2) ng/L, p < 0.001); the same relationship was observed for PP (38.9 (10.2-147.9) or 28.1 (7.9-100.0) vs 89.1 (38.0-208.9) and 75.8 (30.1-190.6) ng/L, p < 0.01), respectively. The lowest levels of GIP and PP concentrations were found in PDAC patients with new-onset diabetes/prediabetes and weight loss > 2 kg (p < 0.001). CONCLUSIONS: We conclude that GIP and PP plasma concentrations are lower in pancreatic cancer irrespective of the degree of glucose intolerance as compared to Type 2 diabetic patients and healthy controls. In new onset diabetes especially if associated with weight loss, these changes may represent a new clue for the diagnosis of PDAC.
3rd Department of Internal Medicine and Laboratory for Endocrinology and Metabolism Prague Czechia
Department of Biochemistry and Experimental Oncology Prague Czechia
References provided by Crossref.org
